MedTrace Logo

Evaluating the Risk of Serious Ventricular Arrhythmia and Sudden Cardiac Death Among Users of Domperidone

NCT00925457 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1608

Last updated 2016-07-19

No results posted yet for this study

Summary

The purpose of this retrospective observational study is to obtain information to confirm or contradict the results of prior studies on domperidone and sudden cardiac death. The population studied are the Saskatchewan residents who used domperidone or another type of medication known as a Proton Pump Inhibitor (PPI) between 1990 and 2005. Information will be collected from various sources including the Saskatchewan Health (SH) database and Cancer Registry.

Conditions

  • Arrhythmias, Cardiac

Interventions

OTHER

No Intervention

Neither current domperidone nor current PPI

DRUG

Current Domperidone

Current domperidone at any dose, regardless of proton pump inhibitor status

DRUG

Current proton pump inhibitor (PPI)

Current PPI and not current dapoxetine

Sponsors & Collaborators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Eligibility

Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-03-31
Completion
2009-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00925457 on ClinicalTrials.gov